StreetAlpha.app
Home › Stocks › CMPS

COMPASS Pathways plc (CMPS)

Healthcare
$7.98
▼ −3.51%
LAST CLOSE · NOV 17

COMPASS Pathways is a UK biotechnology company developing COMP360, a psilocybin-based treatment for serious mental health conditions. It last closed at $7.98 on Nov 17, down 3.51% on the day. The average 12-month price target from 2 analysts is $37.50 (+369.9% from the last close), with a high of $65.00 and a low of $10.00.

AI Auto Pilots
Is CMPS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$266.3M
EPS (diluted)
−$2.34
Valuation
Market cap
$1.1B
141.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$444.0M
At Sep 30
Debt
$51.0M
At Sep 30
Shareholder equity
$142.1M
Shares outstanding
141.7M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$71.7M−$71.7MFY2021FY2022: −$91.5M−$91.5MFY2022FY2023: −$118.5M−$118.5MFY2023FY2024: −$155.1M−$155.1MFY2024FY2025: −$287.9M−$287.9MFY2025

From CMPS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated CMPS in the past 90 days, not enough for a consensus
Average 12-month target
$37.50
▲ 369.9% upside

Based on 2 analysts who set a price target on CMPS in the past 90 days. The average target is $37.50, with a high of $65.00 and a low of $10.00, compared with the last close of $7.98.

$3$25$48$70PAST 27 TRADING DAYS12-MONTH TARGETSHIGH $65AVG $37.50LOW $10May 22LAST CLOSE+12 MO$3$25$48$70PAST 27 DAYSTARGETSHIGH $65AVG $37.50LOW $10May 22LAST CLOSE+12 MO
Highest target$65.00
Average target$37.50
Lowest target$10.00
Latest rating changes
HC Wainwright & Co.Reiterated
Nov 9Buy$65
Wells FargoTarget lowered
Nov 4Hold$13 → $10
HC Wainwright & Co.Maintained
Aug 7Buy$65
B. Riley SecuritiesTarget raised
Aug 6Buy$17 → $22
Wells FargoInitiated
Jul 27Hold$13
DateFirmActionRatingPrice target
Nov 9HC Wainwright & Co.ReiteratedBuy$65
Nov 4Wells FargoTarget loweredHold$13 → $10
Aug 7HC Wainwright & Co.MaintainedBuy$65
Aug 6B. Riley SecuritiesTarget raisedBuy$17 → $22
Jul 27Wells FargoInitiatedHold$13
Loading…

Technical Analysis

CMPS · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 24% below its 20 day and 46% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $7.72, and the nearest resistance the Pivot at $8.07.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$15.8752 week high+98.9%
$12.39100 day average+55.3%
$11.6750 day average+46.2%
$10.50200 day average+31.6%
$9.8820 day average+23.8%
$9.50Swing high (Nov 11)+19.0%
$8.32Pivot R1+4.3%
$8.07Pivot+1.1%
$7.98Last close
$7.72Pivot S1−3.3%
$7.54Swing low (Nov 2)−5.5%
$4.8852 week low−38.8%
Indicators
RSI (14)32.33Weak, oversold below 30Neutral
MACD-0.93Below its signal lineBearish
Stochastic17.7Near the bottom of its rangeOversold
ADX (14)34.9Trending down
Williams %R-91.1Oversold below −80, overbought above −20Oversold
CCI (20)-88.5Oversold below −100, overbought above 100Neutral
Rate of change−7.1%Change over 10 sessionsBearish
ATR (14)$0.79Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CMPS

What happened before

See how CMPS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CMPS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CMPS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CMPS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CMPS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲127 buying vs 96 selling
  • ▲Held by funds +5.9 pts
  • ▲Funds holding +12
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding237225+5.3%
In funds' top 10910−10.0%
Held by funds70.6%64.7%+5.9 pts
New / increased50 / 7760 / 74−5.2%
Reduced / sold out56 / 4048 / 30+23.1%
Put/call ratio0.130.10+25.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CMPS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPS is in one of them and how their past CMPS trades turned out.

CMPS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CMPS in an article yet. Here's the latest on the wider market.

About COMPASS Pathways

COMPASS Pathways is a biotechnology company based in the United Kingdom. It is developing COMP360, a treatment built around psilocybin for serious mental health conditions, with its current focus on depression that has not responded to standard medicines. The company is also running a clinical trial for PTSD. If approved, it plans to offer the treatment to patients through healthcare providers in the U.S.

Headquarters
Chesire, United Kingdom
Founded
2016